Blase Polite, MD

Advice to GI oncologists in the community on using ctDNA testing to detect minimal residual disease and inform treatment decisions in colorectal cancer.

Abstracts presented during ASCO GI 2022 and other initiatives in clinical trials, assessing treatment strategies for patients with colorectal cancer based on ctDNA negativity or positivity.

An overview of the design of the CIRCULATE-US study, set to further explore the potential of ctDNA testing in colorectal cancer.

Implications of the GALAXY study in CIRCULATE-Japan, in terms of utilizing ctDNA to guide decisions for adjuvant chemotherapy in colorectal cancer.

Key takeaways of a recent article highlighting the use of ctDNA analyses for the assessment of recurrence risk, benefit of adjuvant therapy, and early relapse detection after treatment in colorectal cancer patients.

How ctDNA testing can be used in the preoperative and postoperative settings to help oncologists make informed treatment decisions.

An overview of the ctDNA testing platforms and the potential clinical applications of ctDNA testing across the colorectal cancer disease continuum.